EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

 
• By Eliza Slawther and Sarah Karlin-Smith
  
Roche’s gene therapy Elevidys did not meet its primary endpoint in a Phase III trial. (Shutterstock)

More from Cell & Gene Therapies

More from EU CHMP